CRISPR: Move Beyond Differences
By Charis Thompson,
Nature
| 06. 24. 2015
Untitled Document
This autumn, researchers and other experts will come together to discuss the scientific, ethical and policy issues associated with gene-editing research in humans. Plans for the international meeting were announced by the US National Academy of Sciences and the National Academy of Medicine after a study was published in which researchers used a gene-editing tool known as CRISPR to modify the genomes of non-viable human embryos1.
Whether this meeting and others like it, planned in the United States, can help to forge a path for gene editing that takes into account all the relevant needs and concerns will depend on what efforts are made to integrate the diverse perspectives of people with different expertise and values. A first step to such integration is understanding how different perspectives arise.
One division in cares and concerns seems at times to fall along stereotypical gender lines. This was powerfully demonstrated during a meeting in Atlanta, Georgia, last month on biotechnology and ethics. About 200 global thought leaders gathered at BEINGS 2015 to “reach consensus on the direction of biotechnology...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...